A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on <i>ex vivo</i> platelet reactivity
Joseph A. Jakubowski(Indiana Biosciences Research Institute), Christopher D. Payne(Eli Lilly (United States)), Timothy Mant(IQVIA (United Kingdom)), Andrew L. Frelinger(University of Nottingham), D. Richard Lachno(Alzheimer's Association), Chunmei Zhou(Eli Lilly (United States)), Kenneth J. Winters(Eli Lilly (United States)), Jo Howard(National Health Service), David S. Small(Eli Lilly (United States)), Stipo Jurčević(King's College London)
Cited by 24
Related Papers
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
|New England Journal of Medicine|2013|961
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617